Amylyx Pharmaceuticals, Inc. AMLX

NASDAQHealth TechnologyUnited States

$30.29+0.43 (+1.44%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 28.8630.72
52-week range: 10.8341.14

Financial health

– / 5

Analyst view · 12 firms

Buy11 buy · 1 hold · 0 sell

Avg. target $43.00 (+42.0%)

Prices may be delayed and are for informational purposes only - not investment advice.

Amylyx Pharmaceuticals, Inc. AMLX

NASDAQHealth TechnologyUnited States

$30.29+0.43 (+1.44%)

Market closed· Nov 13, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range: 28.8630.72
52-week range: 10.8341.14

Financial health

– / 5

Analyst view · 12 firms

Buy11 buy · 1 hold · 0 sell

Avg. target $43.00 (+42.0%)

Valuation from filings

Calculated from the tables below and the current price ($30.29) · LTM · 2026/9 · 2026-09-30

P/E: —EPS $-1.44
P/B: 4.56BV/share $6.64
P/S: —
Return on equity: -21.7%Net income / equity
Net margin: —
Free cash flow yield: -3.3%Free cash flow / market cap

Revenue and net income

Fiscal year · $ millions · net margin below

RevenueNet Income

Financial statements

$ thousands · Under each value: change against a year earlier

Upgrade to MakklerPRO to see every row.Upgrade to MakklerPRO

Fiscal year	2021	2022	2023	2024	2025	LTM
Income Statement
Revenue	285	22,230+7,700%	380,786+1,613%	87,371-77%	0–	—
Operating expenses
Operating Income
Pre-tax income
Income tax (expense) / benefit
Net Income	(87,931)	(198,375)+126%	49,271turned profitable	(301,743)turned to a loss	(144,735)-52%	(163,195)
Earnings per share ($)
Margins
Operating margin
Net margin

Taken from the company's own 10-K and 10-Q filings via the SEC's XBRL data service. The "LTM" column is the last completed fiscal year plus the current year to date, minus the same period a year earlier. Lines a company tags with a non-standard label are left blank rather than filled with an approximation. Not investment advice.